Epidermolysis Bullosa Therapeutics

PUBLISHED: August 16, 2024

PAGES: 121 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Epidermolysis Bullosa Therapeutics Market to Reach US$8.1 Billion by 2030

The global market for Epidermolysis Bullosa Therapeutics estimated at US$4.1 Billion in the year 2023, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 10.2% over the analysis period 2023-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Analgesics segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 8.6% CAGR

The Epidermolysis Bullosa Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Epidermolysis Bullosa Therapeutics Market - Key Trends and Drivers Summarized

Epidermolysis Bullosa (EB) is a rare, inherited connective tissue disorder that results in the skin being extremely fragile and prone to blistering and tearing from minor friction or trauma. The severity of EB can vary widely, with some forms being life-threatening. Current therapeutic approaches primarily focus on managing symptoms and preventing complications, such as infections and chronic wounds. Traditional treatments include wound care, pain management, nutritional support, and infection control. However, recent advancements in gene therapy, protein replacement therapy, and stem cell therapy offer promising new avenues for more effective and targeted treatments. Researchers and pharmaceutical companies are actively exploring these innovative approaches to address the underlying genetic causes of EB, aiming to improve the quality of life for patients significantly.

The market for Epidermolysis Bullosa therapeutics has been witnessing significant developments driven by technological advancements and a deeper understanding of the disease's genetic basis. One of the major trends is the increasing focus on gene editing technologies, such as CRISPR-Cas9, which have shown potential in correcting genetic mutations responsible for EB. Additionally, protein replacement therapies, which aim to restore the missing or dysfunctional proteins in EB patients, are also gaining traction. Stem cell therapy represents another promising frontier, with clinical trials exploring the use of stem cells to regenerate healthy skin tissue. Furthermore, there is a growing trend towards personalized medicine, where treatments are tailored to the specific genetic mutations and characteristics of individual patients. This approach not only enhances treatment efficacy but also minimizes potential side effects.

The growth in the Epidermolysis Bullosa therapeutics market is driven by several factors. Technological advancements in gene therapy, protein replacement therapy, and stem cell therapy are expanding the treatment options available for EB, thereby driving market growth. The rising prevalence of EB, coupled with increased awareness and early diagnosis, is also contributing to the growing demand for effective therapies. Additionally, substantial investments in research and development by pharmaceutical companies and academic institutions are fostering innovation and accelerating the development of new treatments. Regulatory support, including orphan drug designations and fast-track approvals, is encouraging the development of EB therapies. Furthermore, the increasing adoption of personalized medicine approaches is generating demand for targeted and individualized treatments. Lastly, patient advocacy groups and public health initiatives are playing a crucial role in raising awareness and driving the adoption of new therapies, ultimately contributing to the market's expansion.

Select Competitors (Total 86 Featured) -

Abeona Therapeutics
Aegle Therapeutics
Alphyn Biologics
Castle Creek Biosciences, Inc.
Chiesi Global Rare Disease
Eloxx Pharmaceuticals Inc
Holostem Terapie Avanzate Srl
InMed Pharmaceuticals Inc.
Krystal Biotech
Prime Therapeutics
Quoin Pharmaceuticals
RegeneRx Biopharmaceuticals, Inc.
RHEACELL
Shionogi & Co., Ltd.
TWI Biotechnology, Inc.

Product Code: MCP26839

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Epidermolysis Bullosa Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Epidermolysis Bullosa Expands Addressable Market Opportunity
- Advancements in Gene Therapy Propel Growth in Epidermolysis Bullosa Therapeutics Market
- Innovative Protein Replacement Therapies Strengthen Business Case for EB Treatments
- Stem Cell Therapy Developments Accelerate Demand for Novel EB Therapeutics
- Increasing Awareness and Early Diagnosis Spur Growth in EB Therapeutics Market
- Integration of Digital Health Technologies Throws the Spotlight on EB Treatment Advancements
- Growing Use of CRISPR-Cas9 Technology Expands Addressable Market for EB Treatments
- Emerging Combination Therapies Propel Growth in Epidermolysis Bullosa Market
- Economic Burden of EB on Patients and Healthcare Systems Drives Demand for Cost-Effective Therapies
- Increasing Healthcare Expenditure Accelerates Demand for Epidermolysis Bullosa Treatments
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Epidermolysis Bullosa Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Epidermolysis Bullosa Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 16: USA 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 19: Canada 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
JAPAN
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 22: Japan 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
CHINA
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 24: China Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 25: China 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
EUROPE
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Epidermolysis Bullosa Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
FRANCE
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: France Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: France 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
GERMANY
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Germany 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Italy 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: UK 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: Rest of Europe Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: Rest of Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: Asia-Pacific Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: Asia-Pacific 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
REST OF WORLD
- TABLE 50: Rest of World Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 51: Rest of World Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: Rest of World 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030